港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

生物医药B类股

619.832

-11.249-1.78%

涨家数：6

跌家数：25

平家数：3

市盈率：- -

高：633.508

开：631.081

低：614.387

收：631.081

成交量：8,515.90万

成交额：17.99亿

市值：3,809.30亿

流通市值：3,408.71亿

数据加载中...

总览新闻资讯

众生药业(002317.SZ)：创新药研发项目临床试验进度、审评和审批结果具有不确定性

网上药店破700亿，51个品牌销售过亿

米内零售观察

看，这家生物医药“梦工厂”的“药”强之路

股价上涨超140%，ADC领域的“隐形赢家”

医药生物行业定期报告：资金明显回流医药板块关注有变化的佰仁医疗！

摘掉“医美面膜”标签后，敷尔佳靠什么征服消费者？

深耕双抗领域15年，友芝友生物周鹏飞：中国创新药正在走向产业高潮

Tides 周递 | 全球多肽和寡核苷酸药物一周要闻（11.8-11.14）

康希诺施展财技：公积金一次性抹平14.5亿元亏损

中国经营报

南华金融(00619)拟设立合营公司进军AI制药、美妆科技及抗衰老消费市场等高增长领域

人福医药：公司始终专注于医药主业的发展

国药控股主业遇冷，医药流通龙头的增长神话还能延续吗？

华夏时报网

能源仍是涨停热点板块！医药商业逆势崛起，补涨行情来了？

每日经济新闻

科兴制药(688136.SH)：科益医药拟询价转让5%公司股份

富祥药业：他唑巴坦、舒巴坦是公司主要医药产品

生物制造被提到新高度创新药、中药等细分领域备受关注

金融投资报

涨价机会梳理：有色+锂电材料+化工+医药（机构闭门会议实录）

新股消息 | 融泰药业拟港股上市中国证监会要求补充说明近一年内新增股东入股价格的合理性等

ETF日报：创新药板块或存在盈利和估值抬升的可能，值得关注

执行董事杨建新增持基石药业(02616)11.75万股每股均价约5.42港元

智通财经网

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/BK1574/news?page=3"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物医药B类股","latestPrice":619.83203,"timestamp":1763366893506,"preClose":631.0813,"halted":0,"volume":85158970,"delay":0,"changeRate":-0.017825,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":-11.249268,"latestTime":"11-17 16:00:00","open":631.0813,"high":633.5082,"low":614.387,"amount":1799340647,"amplitude":0.030299,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1763429400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1763343000000,1763352000000],[1763355600000,1763366400000]],"pbRate":5.386036,"peRate":-44.459922,"turnoverRate":0.003108,"increases":6,"decrements":26,"flats":1,"marketCap":380930473472,"floatMarketCap":340871157584},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":633.5082,"amplitude":0.030299,"preClose":631.0813,"low":614.387,"pbRate":"5.386036","latestPrice":619.83203,"volume":85158970,"delay":0,"open":631.0813,"prevYearClose":331.1933,"prevWeekClose":631.081,"prevMonthClose":618.706,"prevQuarterClose":752.859,"fiveDayClose":602.134,"twentyDayClose":646.836,"sixtyDayClose":790.38,"secType":"PLATE","market":"HK","turnoverRate":0.003108,"peRate":-44.459922,"marketCap":380930473472,"floatMarketCap":340871157584,"timestamp":1763366893506,"nameCN":"生物医药B类股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":6,"down":25,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2583666072","title":"众生药业(002317.SZ)：创新药研发项目临床试验进度、审评和审批结果具有不确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2583666072","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583666072?lang=zh_cn&edition=fundamental","pubTime":"2025-11-16 16:45","pubTimestamp":1763282731,"startTime":"0","endTime":"0","summary":"创新药研发项目的临床试验进度、审评和审批的结果以及未来产品市场竞争格局都具有一定的不确定性。药品能否获批上市以及获批上市的时间、上市后的生产和销售情况存在不确定性。用于治疗成人单纯性甲型流感的小分子创新药昂拉地韦片已获得国家药品监督管理局批准上市，是全球首款流感RNA聚合酶PB2蛋白抑制剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369698.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","002317","BK0188","BK0077","06978","BK1574","BK1161","159992"],"gpt_icon":0},{"id":"2583661268","title":"网上药店破700亿，51个品牌销售过亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2583661268","media":"米内零售观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583661268?lang=zh_cn&edition=fundamental","pubTime":"2025-11-16 14:00","pubTimestamp":1763272845,"startTime":"0","endTime":"0","summary":"米内网数据显示，2024年网上药店药品的销售规模已突破700亿元，2025上半年增长了20.36%。51个药品卖过亿！整体来看，51个销售额过亿的品牌中有32个品牌有正增长，最高增幅是2267.10%；19个品牌负增长，降幅最高为55.44%，诺和诺德的司美格鲁肽注射液、乐福思的他达拉非片等7个品牌降幅超过20%，需加倍努力。国药集团手握2个过亿品牌，均为化学药，合揽超过5亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251116140323a6fc9c0d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251116140323a6fc9c0d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","01477","BK1606","BK1574","03320","06887","BK1197","BK1515","BK1521","00874"],"gpt_icon":0},{"id":"2583662616","title":"看，这家生物医药“梦工厂”的“药”强之路","url":"https://stock-news.laohu8.com/highlight/detail?id=2583662616","media":"南京日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583662616?lang=zh_cn&edition=fundamental","pubTime":"2025-11-16 08:00","pubTimestamp":1763251200,"startTime":"0","endTime":"0","summary":"让老百姓用得上、用得起创新药看，这家生物医药“梦工厂”的“药”强之路□ 南京日报/紫金山新闻记者 张安琪蹲点主题：生物制造从技术突破到产业升级蹲点点位：正大天晴药业集团生病时，一粒药丸、一支药剂，能守护健康，甚至能为生命续航。一款生物药的“成长之路”从冷冻罐中的细胞种子开始。陆建胜表示，这条万升产线自建成以来，已生产百余批次生物药，零安全事故记录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251116083808a4a45ece&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251116083808a4a45ece&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","IE00BZ08YS42.EUR","BK1521","IE00BZ08YT58.USD","BK1589","BK1574","01177","BK1515","BK1191","BK1161","06978","IE00BZ08YR35.GBP"],"gpt_icon":0},{"id":"2583669633","title":"股价上涨超140%，ADC领域的“隐形赢家”","url":"https://stock-news.laohu8.com/highlight/detail?id=2583669633","media":"药渡","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583669633?lang=zh_cn&edition=fundamental","pubTime":"2025-11-16 07:30","pubTimestamp":1763249459,"startTime":"0","endTime":"0","summary":"2025年10月，中国创新药再次被ADC领域的巨额BD交易彻底点燃。在这场ADC狂欢中，最引人注目的除了手握重磅管线的创新药企，还有ADC领域的“卖铲人”——皓元医药。今年以来，截至10月31日，皓元医药的股价从35.47元/股，一路上涨至最高88.38元/股，涨幅超过140%，成为资本市场的“隐形赢家”。3ADC黄金时代皓元医药股价大幅上涨，与近些年ADC药物市场的爆发密切相关。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251116090353a6fc3962&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251116090353a6fc3962&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","03692","09995","BK1574","BK1191","06978","02615","BK1161","BK1583","LU1969619763.USD","01801","LU2328871848.SGD"],"gpt_icon":0},{"id":"2583619476","title":"医药生物行业定期报告：资金明显回流医药板块 关注有变化的佰仁医疗！","url":"https://stock-news.laohu8.com/highlight/detail?id=2583619476","media":"华福证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583619476?lang=zh_cn&edition=fundamental","pubTime":"2025-11-16 00:00","pubTimestamp":1763222400,"startTime":"0","endTime":"0","summary":"新品连续上市放量+瓣膜集采预期，动物源胶原蛋白上市在即，关注佰仁医疗。2）佰仁医疗：①新品连续上市，25 年12 款产品审评中，为公司成立来提交最多一年；收入端已连续4 季度收入30%增速，预计未来保持高增态势。③布局三款动物源胶原蛋白，其中I 型已进入注册审查阶段，预计近期有望获批。供不应求现状，有望上市后即受到需求拉动放量。收入高增有支撑，动物源胶原蛋白上市催化，26 年增长有望提速，建议关注佰仁医疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251116184631a6fcfc7c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251116184631a6fcfc7c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09606","01801","BK1515","LU2543165471.USD","BK1161","09939","HK0000252160.HKD","HK0000500386.USD","HK0000252152.HKD","BK1574"],"gpt_icon":0},{"id":"2583658442","title":"摘掉“医美面膜”标签后，敷尔佳靠什么征服消费者？","url":"https://stock-news.laohu8.com/highlight/detail?id=2583658442","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583658442?lang=zh_cn&edition=fundamental","pubTime":"2025-11-15 20:52","pubTimestamp":1763211170,"startTime":"0","endTime":"0","summary":"而进入2025年后，敷尔佳更是呈现营利双位数下滑态势。2025年前三季度，敷尔佳营收同比减少11.54%至12.97亿元，归属净利润同比减少36.73%至3.25亿元。业绩下滑，引起外界对敷尔佳资金健康的隐忧。截至2024年末，敷尔佳线下收入占比仍达45.04%。2025年前三季度，敷尔佳销售费用率已增至47.88%，而2018年销售费用率仅5.72%。此外，敷尔佳前三季度预付款项暴涨233.77%，公司将其归结于预付平台推广费用款、委托加工费及原材料增加所致。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1763099940892981070","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["09996","BK1100","BK1583","BK1574","02367","SG9999004311.SGD","LU2488822045.USD","BK1207","09997","BK1222"],"gpt_icon":0},{"id":"2583665794","title":"深耕双抗领域15年，友芝友生物周鹏飞：中国创新药正在走向产业高潮","url":"https://stock-news.laohu8.com/highlight/detail?id=2583665794","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583665794?lang=zh_cn&edition=fundamental","pubTime":"2025-11-15 13:56","pubTimestamp":1763186186,"startTime":"0","endTime":"0","summary":"M701即将申请上市，友芝友生物将其中国区权益以超过20亿元的预期销售额转让给正大天晴，自己保留海外权益和销售提成。在双抗领域的蓝海中，周鹏飞和他的团队正以坚定的步伐，书写着中国生物医药创新的新篇章。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511151404519505db72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511151404519505db72&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","02496","06978"],"gpt_icon":0},{"id":"2583765244","title":"Tides 周递 | 全球多肽和寡核苷酸药物一周要闻（11.8-11.14）","url":"https://stock-news.laohu8.com/highlight/detail?id=2583765244","media":"多肽圈","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583765244?lang=zh_cn&edition=fundamental","pubTime":"2025-11-15 09:00","pubTimestamp":1763168442,"startTime":"0","endTime":"0","summary":"临床拟用于慢性乙型肝炎病毒感染的治疗。此外，SD 大鼠与食蟹猴的重复给药毒性试验显示，YKYY013 注射液具有良好的安全性和耐受性。该研究在263名不合并2型糖尿病的肥胖或伴有至少一种体重相关合并症的超重成人参与者中，评估了eloralintide的安全性与有效性。在第48周时，eloralintide各剂量组均达到主要终点，平均体重降幅为9.5%至20.1%，优于安慰剂组0.4%的平均降幅。研究显示，eloralintide可能通过影响饱腹感来减少热量摄入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251115092746a4a2ad83&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251115092746a4a2ad83&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","BK1589","01672","BK1515","LU2328871848.SGD","HK0000165453.HKD","LU2097828805.USD","LU2097828557.USD","LU0455707207.USD","01801","LU2097828474.EUR","LU2097828714.EUR","LU0502904849.HKD","BK1574","BK1161","LU2488822045.USD","LU2097828631.EUR","LU2242644610.SGD","BK1583"],"gpt_icon":0},{"id":"2583307996","title":"康希诺施展财技：公积金一次性抹平14.5亿元亏损","url":"https://stock-news.laohu8.com/highlight/detail?id=2583307996","media":"中国经营报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583307996?lang=zh_cn&edition=fundamental","pubTime":"2025-11-15 08:24","pubTimestamp":1763166246,"startTime":"0","endTime":"0","summary":"11月7日，康希诺召开董事会会议，审议通过了关于使用公积金弥补亏损的议案，康希诺拟使用母公司盈余公积约1.18亿元和母公司资本公积约13.32亿元，两项合计约14.5亿元用于弥补母公司累计亏损。康希诺此次使用公积金弥补亏损后，为其未来可能进行的分红扫清了障碍。康希诺此次弥补的母公司未分配利润为负的原因主要为以前年度累计的亏损。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251115075458976a4adf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251115075458976a4adf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1574","BK1191","06185","BK1161"],"gpt_icon":0},{"id":"2583504574","title":"南华金融(00619)拟设立合营公司进军AI制药、美妆科技及抗衰老消费市场等高增长领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2583504574","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583504574?lang=zh_cn&edition=fundamental","pubTime":"2025-11-14 22:13","pubTimestamp":1763129639,"startTime":"0","endTime":"0","summary":"智通财经APP讯，南华金融 公布，于2025年11月14日，公司与一家于中国境内注册成立的公司(对方)签署了一份谅解备忘录。投资AI赋能的生物科技领域，是集团落实业务多元化战略的关键一步。董事会相信通过合营公司，集团将进军包括AI制药、美妆科技及抗衰老消费市场等高增长领域，这不仅有助于分散集团现有业务的单一风险，更能为集团开辟极具潜力的新收入与利润来源，实现长期价值的可持续增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369615.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1147","01477","BK1574","00619"],"gpt_icon":0},{"id":"2583022115","title":"人福医药：公司始终专注于医药主业的发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2583022115","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583022115?lang=zh_cn&edition=fundamental","pubTime":"2025-11-14 22:10","pubTimestamp":1763129400,"startTime":"0","endTime":"0","summary":"证券日报网讯人福医药（维权）11月14日在互动平台回答投资者提问时表示，公司始终专注于医药主业的发展，持续推进“归核聚焦”工作，优化资产结构，强化细分领域竞争优势。2025年前三季度，公司实现归母净利润16.89亿元，同比增长6.22%，2025年三季度末公司资产负债率降至40.53%，资产结构持续改善。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-14/doc-infxktkn8977482.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-14/doc-infxktkn8977482.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159938","BK1161","BK0070","600079","BK0188","BK0012","BK1574","BK0028","BK0096","BK1515","BK0239","BK0185","09939"],"gpt_icon":0},{"id":"2583542501","title":"国药控股主业遇冷，医药流通龙头的增长神话还能延续吗？","url":"https://stock-news.laohu8.com/highlight/detail?id=2583542501","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583542501?lang=zh_cn&edition=fundamental","pubTime":"2025-11-14 21:23","pubTimestamp":1763126625,"startTime":"0","endTime":"0","summary":"作为国内医药流通行业的龙头企业，国药控股（股票代码：1099.HK）近期的业绩表现引发了市场的广泛关注。尽管其营收规模在行业内持续保持领先地位，但陷入净利润增长显著放缓的困境。业绩承压的背后，是公司三大核心业务板块集体面临增长挑战。作为营收“压舱石”的医药分销业务增长乏力，医疗器械板块同样未能摆脱增长瓶颈，就连曾被寄予厚望的医药零售业务，其增长也伴随着战略调整的阵痛。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511143565047652.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511143565047652.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1197","BK1500","LU0640798160.USD","BK1515","BK1161","09939","01099","LU1115378108.SGD","BK1574"],"gpt_icon":0},{"id":"2583344346","title":"能源仍是涨停热点板块！医药商业逆势崛起，补涨行情来了？","url":"https://stock-news.laohu8.com/highlight/detail?id=2583344346","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583344346?lang=zh_cn&edition=fundamental","pubTime":"2025-11-14 20:51","pubTimestamp":1763124665,"startTime":"0","endTime":"0","summary":"涨停板方面，今日仍然有较多能源相关概念股涨停，具体来说则是锂电池板块和燃气板块。今日涨停最多的是医药板块，从细分行业来看，医药商业行业涨停股较多。当前医药商业板块现较多涨停股，不排除补涨的可能。市场预计将提振感冒药和流感相关药品的销售需求。主力资金净流入金额占市值比例排名前5的个股分别为中富通、日上集团、京能热力、康芝药业、英联股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114205647a6f99835&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114205647a6f99835&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1574","02039","BK1515","BK1183","BK1507","BK1161"],"gpt_icon":0},{"id":"2583503742","title":"科兴制药(688136.SH)：科益医药拟询价转让5%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2583503742","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583503742?lang=zh_cn&edition=fundamental","pubTime":"2025-11-14 20:15","pubTimestamp":1763122501,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科兴制药(688136.SH)披露股东询价转让计划书，本次拟参与本次询价转让的股东为科益医药，拟转让股份的总数为1006.28万股，占公司总股本的比例为5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369553.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1574","BK1161","688136","159938","BK0239","09939"],"gpt_icon":0},{"id":"2583505330","title":"富祥药业：他唑巴坦、舒巴坦是公司主要医药产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2583505330","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583505330?lang=zh_cn&edition=fundamental","pubTime":"2025-11-14 20:09","pubTimestamp":1763122140,"startTime":"0","endTime":"0","summary":"证券日报网讯富祥药业11月14日发布公告，在公司回答调研者提问时表示，他唑巴坦、舒巴坦是公司主要医药产品，2024年销售收入占公司营业收入40%左右。而6-apa是他唑巴坦、舒巴坦的主要原材料，根据万得数据显示，截至2025年11月3日，6-apa价格较2024年底下降38%。随着其价格下降，将有效提升公司医药制造业务毛利率。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-14/doc-infxkpau4340288.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-14/doc-infxkpau4340288.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK1515","09939","BK1161","BK1574","300497","159938","BK0201"],"gpt_icon":0},{"id":"2583968049","title":"生物制造被提到新高度 创新药、中药等细分领域备受关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2583968049","media":"金融投资报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583968049?lang=zh_cn&edition=fundamental","pubTime":"2025-11-14 19:56","pubTimestamp":1763121412,"startTime":"0","endTime":"0","summary":"有分析人士指出，未来，需求和供给仍将是医药行业的主要逻辑，建议关注创新药、医疗器械、中药、原料药、医疗服务等细分领域的投资机会。AI制图 卿子秀创新药：迈入双轮驱动阶段中国创新药行业已形成以领头企业为引领、大批量优质企业为支撑的金字塔梯队，产业兑现持续性强。截至2025年三季度末，申万中药行业机构持仓比例已低至0.2%，动态市盈率居2021年以来低位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114195858976955d1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114195858976955d1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01877","BK1515","BK1583","06978","BK1161","BK1574"],"gpt_icon":0},{"id":"2583567502","title":"涨价机会梳理：有色+锂电材料+化工+医药（机构闭门会议实录）","url":"https://stock-news.laohu8.com/highlight/detail?id=2583567502","media":"投研大叔","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583567502?lang=zh_cn&edition=fundamental","pubTime":"2025-11-14 19:39","pubTimestamp":1763120377,"startTime":"0","endTime":"0","summary":"电力设备及新能源板块：锂电池材料涨价趋势与FSI添加剂市场潜力中游锂电材料的供需紧张推动价格上涨，推荐关注FSI添加剂市场。锂电材料方面，铜箔和铝箔加工费上涨预期强烈，企业开工率回升，利润空间有望扩大。美国中期选举年，总统上任后到中期选举期间，大宗商品价格尤其是工业金属会出现持续上行趋势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114222645a4a1d773&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114222645a4a1d773&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09696","BK1161","LU1807302812.USD","09939","02899","BK1116","LU1960683339.HKD","LU1993786604.SGD","01772","BK1610","03750","BK1515","02600","BK1574","03347"],"gpt_icon":1},{"id":"2583508925","title":"新股消息 | 融泰药业拟港股上市 中国证监会要求补充说明近一年内新增股东入股价格的合理性等","url":"https://stock-news.laohu8.com/highlight/detail?id=2583508925","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583508925?lang=zh_cn&edition=fundamental","pubTime":"2025-11-14 19:32","pubTimestamp":1763119944,"startTime":"0","endTime":"0","summary":"中国证监会国际司公示10家企业补充材料要求，其中，公示提到要求融泰药业补充说明最近12个月内新增股东入股价格的合理性等事项。中国证监会请融泰药业补充说明以下事项，请律师核查并出具明确的法律意见：一、请说明最近12个月内新增股东入股价格的合理性，该等入股价格之间存在差异的原因，是否存在利益输送。据招股书，融泰药业是中国领先的院外医药服务商，专注于数字化营销和供应链解决方案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369520.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1574","BK1161","09939"],"gpt_icon":0},{"id":"2583701935","title":"ETF日报：创新药板块或存在盈利和估值抬升的可能，值得关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2583701935","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583701935?lang=zh_cn&edition=fundamental","pubTime":"2025-11-14 19:21","pubTimestamp":1763119260,"startTime":"0","endTime":"0","summary":"受隔夜纳指再次大跌超2%等利空因素影响，今日A股情绪较弱，呈现冲高回落走势。截止收盘，上证指数缩量收阴，报3990.49点，下跌-0.97%，深证成指跌-1.93%，创业板指跌-2.82%。两市跌多涨少，不足2000家上涨，3300余家下跌。成交方面，沪深两市成交额不足2万亿，交投较为冷清。其中，海外映射较强、前期表现强势的AI、通信、芯片等板块跌幅居前。创新药板块或存在盈利和估值抬升的可能，值得投资者关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-11-14/doc-infxkpaw2923616.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","159992","BK4588","BK1574","FDN","BK4585","BK1161","BK4550"],"gpt_icon":0},{"id":"2583570157","title":"执行董事杨建新增持基石药业(02616)11.75万股 每股均价约5.42港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2583570157","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583570157?lang=zh_cn&edition=fundamental","pubTime":"2025-11-14 18:52","pubTimestamp":1763117574,"startTime":"0","endTime":"0","summary":"香港联交所最新资料显示，11月13日，执行董事杨建新增持基石药业(02616)11.75万股，每股均价5.4183港元，总金额约为63.67万港元。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20251114/20251114185330_60112.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251114/20251114185330_60112.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369479.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","02616","BK1574"],"gpt_icon":0}],"pageSize":20,"totalPage":31,"pageCount":3,"totalSize":618,"code":"91000000","status":"200"}]}}